EQL Pharma licenses Memprex to Pharmacenter for Hungary market
Reuters2026/08/12 06:35- EQL Pharma licensed exclusive rights to sell Memprex (methenamine hippurate) in Hungary to local drugmaker Pharmacenter.
- Deal includes three milestone payments totaling a five-digit amount in EUR, conditional on meeting agreed sales targets.
- EQL will supply the product to Pharmacenter at a transfer price.
- Hungary currently has no methenamine hippurate product on the market; Memprex targets prophylaxis for recurrent urinary tract infections.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US dollar has fallen for two consecutive months, and the US Treasury's buyback has forced speculators to retreat; the hawkish stance of Waller only resulted in a one-day rebound.
The US dollar extended its decline in August, with the Bloomberg Dollar Spot Index down 0.9%, marking its second consecutive monthly drop. US Treasury Secretary Besant expanded the Treasury buyback program, sparking market speculation that US policies are intended to guide the dollar lower. Although Fed Chair Walsh reaffirmed the 2% inflation target and fueled expectations of further rate hikes, Wells Fargo warned that the Fed may not deliver on these expectations and the dollar’s weakness could persist.
Strategy director Jarrod M. Patten sells 1,850 shares for $240,500
nCino SVP of Accounting Jeanette Sellers sells 690 shares for $15,666.45
Crypto prices
More
